競合的阻害薬、競合的阻害剤

WordNet

limit, block, or decrease the action or function of; "inhibit the action of the enzyme"; "inhibit the rate of a chemical reaction"
control and refrain from showing; of emotions, desires, impulses, or behavior (同)bottle up, suppress
limit the range or extent of; "Contact between the young was inhibited by strict social customs"
showing a fighting disposition; "highly competitive sales representative"; "militant in fighting for better wages for workers"; "his self-assertive and ubiquitous energy" (同)militant
involving competition or competitiveness; "competitive games"; "to improve ones competitive position" (同)competitory
subscribing to capitalistic competition (同)free-enterprise, private-enterprise
a substance that retards or stops an activity

PrepTutorEJDIC

〈感情・欲望・行動・作用など〉‘を'抑制する / (…しないように)〈人〉‘を'抑制する,妨げる《+『名』+『from』+『名』(do『ing』)》
競争の,競争による
抑制する人(物) / 化学反応抑制剤

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/10/30 10:58:10」(JST)

wiki en

Competitive inhibition is a form of enzyme inhibition where binding of the inhibitor to the active site on the enzyme prevents binding of the substrate and vice versa.^[1]^[2]

Most competitive inhibitors function by binding reversibly to the active site of the enzyme.^[1] As a result, many sources state that this is the defining feature of competitive inhibitors.^[3]^[4] This, however, is a misleading oversimplification, as there are many possible mechanisms by which an enzyme may bind either the inhibitor or the substrate but never both at the same time.^[1] For example, allosteric inhibitors may display competitive, non-competitive, or uncompetitive inhibition.^[1]

Mechanism

Diagram showing competitive inhibition

In competitive inhibition, at any given moment, the enzyme may be bound to the inhibitor, the substrate, or neither, but it cannot bind both at the same time.

In virtually every case, competitive inhibitors bind in the same binding site as the substrate, but same-site binding is not a requirement. A competitive inhibitor could bind to an allosteric site of the free enzyme and prevent substrate binding, as long as it does not bind to the allosteric site when the substrate is bound.

In competitive inhibition, the maximum velocity () of the reaction is unchanged, while the apparent affinity of the substrate to the binding site is decreased (the dissociation constant is apparently increased). The change in (Michaelis-Menten constant) is parallel to the alteration in . Any given competitive inhibitor concentration can be overcome by increasing the substrate concentration in which case the substrate will outcompete the inhibitor in binding to the enzyme.

Competitive inhibition can also be allosteric, as long as the inhibitor and the substrate cannot bind the enzyme at the same time.

Another possible mechanism for allosteric competitive inhibition.

Equation

Competitive inhibition increases the apparent value of the Michaelis-Menten constant, , such that initial rate of reaction, , is given by

where , is the inhibitor's dissociation constant and is the inhibitor concentration.

remains the same because the presence of the inhibitor can be overcome by higher substrate concentrations. , the substrate concentration that is needed to reach , increases with the presence of a competitive inhibitor. This is because the concentration of substrate needed to reach with an inhibitor is greater than the concentration of substrate needed to reach without an inhibitor.

Derivation

In the simplest case of a single-substrate enzyme obeying Michaelis-Menten kinetics, the typical scheme

E + S \, \overset{k_1}\underset{k_{-1}} \rightleftharpoons \, ES \, \overset{k_2} {\longrightarrow} \, E + P

is modified to include binding of the inhibitor to the free enzyme:

EI + S \, \overset{k_{-3}}\underset{k_3} \rightleftharpoons \, E + S + I \, \overset{k_1}\underset{k_{-1}} \rightleftharpoons \, ES + I \, \overset{k_2} {\longrightarrow} \, E + P + I

Note that the inhibitor does not bind to the ES complex and the substrate does not bind to the EI complex. It is generally assumed that this behavior is indicative of both compounds binding at the same site, but that is not strictly necessary. As with the derivation of the Michaelis-Menten equation, assume that the system is at steady-state, i.e. the concentration of each of the enzyme species is not changing.

Furthermore, the known total enzyme concentration is , and the velocity is measured under conditions in which the substrate and inhibitor concentrations do not change substantially and an insignificant amount of product has accumulated.

We can therefore set up a system of equations:

(1)

(2)

(3)

(4)

where , and are known. The initial velocity is defined as , so we need to define the unknown in terms of the knowns , and .

From equation (3), we can define E in terms of ES by rearranging to

Dividing by gives

As in the derivation of the Michaelis-Menten equation, the term can be replaced by the macroscopic rate constant :

(5)

Substituting equation (5) into equation (4), we have

Rearranging, we find that

At this point, we can define the dissociation constant for the inhibitor as , giving

(6)

At this point, substitute equation (5) and equation (6) into equation (1):

Rearranging to solve for ES, we find

(7)

Returning to our expression for , we now have:

Since the velocity is maximal when all the enzyme is bound as the enzyme-substrate complex, . Replacing and combining terms finally yields the conventional form:

(8)

References

^ ^a ^b ^c ^d "Types of Inhibition". NIH Center for Translational Therapeutics. Retrieved 2 April 2012.
^ "Competitive Inhibition". Retrieved 2 April 2012.
^ "Enzyme Inhibitors".
^ "Enzyme Inhibition". Retrieved 2 April 2012.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. HIV感染症の治療に用いる抗レトロウイルス薬の概要 overview of antiretroviral agents used to treat hiv
2. 排卵誘発の概要 overview of ovulation induction
3. 抗潰瘍薬：作用機序、薬理作用、副作用 antiulcer medications mechanism of action pharmacology and side effects
4. 肺の炎症性筋線維芽細胞性腫瘍（形質細胞肉芽腫） inflammatory myofibroblastic tumor plasma cell granuloma of the lung
5. ガンシクロビルおよびバルガンシクロビル：概要 ganciclovir and valganciclovir an overview

English Journal

Evaluation of the published kinase inhibitor set to identify multiple inhibitors of bacterial ATP-dependent mur ligases.

Hrast M, Rožman K, Ogris I, Škedelj V, Patin D, Sova M, Barreteau H, Gobec S, Grdadolnik SG, Zega A.
Journal of enzyme inhibition and medicinal chemistry. 2019 Dec;34(1)1010-1017.
The Mur ligases form a series of consecutive enzymes that participate in the intracellular steps of bacterial peptidoglycan biosynthesis. They therefore represent interesting targets for antibacterial drug discovery. MurC, D, E and F are all ATP-dependent ligases. Accordingly, with the aim being to
PMID 31072165

SAR and molecular mechanism studies of monoamine oxidase inhibition by selected chalcone analogs.

Shalaby R, Petzer JP, Petzer A, Ashraf UM, Atari E, Alasmari F, Kumarasamy S, Sari Y, Khalil A.
Journal of enzyme inhibition and medicinal chemistry. 2019 Dec;34(1)863-876.
The present study describes the synthesis of a series of 22 chalcone analogs. These compounds were evaluated as potential human MAO-A and MAO-B inhibitors. The compounds showed varied selectivity against the two isoforms. The IC values were found to be in the micromolar to submicromolar range. The K
PMID 30915862

Exploring the activity of polyamine analogues on polyamine and spermine oxidase: methoctramine, a potent and selective inhibitor of polyamine oxidase.

Di Paolo ML, Cervelli M, Mariottini P, Leonetti A, Polticelli F, Rosini M, Milelli A, Basagni F, Venerando R, Agostinelli E, Minarini A.
Journal of enzyme inhibition and medicinal chemistry. 2019 Dec;34(1)740-752.
Fourteen polyamine analogues, asymmetric or symmetric substituted spermine (1-9) or methoctramine (10-14) analogues, were evaluated as potential inhibitors or substrates of two enzymes of the polyamine catabolic pathway, spermine oxidase (SMOX) and acetylpolyamine oxidase (PAOX). Compound 2 turned o
PMID 30829081

Japanese Journal

Fluctuation-induced pattern transition in a competitive nonlinear proliferation system

専修自然科学紀要 48, 27-40, 2017-03-05
NAID 120006342769

Role of Glyceraldehyde-derived AGEs and Mitochondria in Superoxide Production in Femoral Artery of OLETF Rat and Effects of Pravastatin

Ｂｉｏｌｏｇｉｃａｌ　＆　Ｐｈａｒｍａｃｅｕｔｉｃａｌ　Ｂｕｌｌｅｔｉｎ, 2017
NAID 130005995237

Potassium oxonate induces acute hyperuricemia in the tree shrew (<i>tupaia belangeri chinensis</i>)

Experimental Animals 66(3), 209-216, 2017
NAID 130005907581

「拮抗阻害剤」

　　[★]

英: competitive inhibitor
同: 競合阻害剤、競争阻害剤

「競合的阻害剤」

　　[★]

英: competitive inhibitor
関: 競合的阻害薬

「競合的阻害薬」

　　[★]

英: competitive inhibitor
関: 競合的阻害剤

「noncompetitive inhibitor」

　　[★]

非競合的阻害薬、非競合的阻害剤

関: non-competitive inhibitor

「non-competitive inhibitor」

　　[★]

非競合的阻害薬、非競合的阻害剤

関: noncompetitive inhibitor

「inhibit」

　　[★]

v.

抑制する、阻害する、阻止する

関: abrogate、block、depress、depression、deter、inhibition、interdict、prevent、prevention、repress、repression、restrain、restraint、suppress、suppression

「inhibitor」

　　[★]

n.

阻害剤、阻害薬、抑制薬、抑制剤、(内在性物質について)インヒビター、抑制物質

関: blocker、depressant、suppressant

「competitive」

　　[★]

競合的な、競合性の、競合する、競争の

関: compete、competition、competitively、competitiveness、contest、rival

[NIH_CTT-1] "Types of Inhibition". NIH Center for Translational Therapeutics. Retrieved 2 April 2012.

[2] "Competitive Inhibition". Retrieved 2 April 2012.

[3] "Enzyme Inhibitors".

[4] "Enzyme Inhibition". Retrieved 2 April 2012.

リンク元	「拮抗阻害剤」「競合的阻害剤」「競合的阻害薬」
拡張検索	「noncompetitive inhibitor」「non-competitive inhibitor」
関連記事	「inhibit」「inhibitor」「competitive」

匿名

検索

案内

案内

competitive inhibitor